Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.50 |
| ▸ | TUBB | P07437 | 2/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725343 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TDP1TUBB4ATUBBTUBA3C | |
| SCHEMBL1939464 | 0.85 | VCAM1 (0.58) | ALDH1A1TDP1TUBB4ATUBBTUBA3C | |
| SCHEMBL16957457 | 0.85 | ALDH1A1 (0.51) | ALDH1A1TDP1TUBB4ATUBBTUBA3C | |
| SCHEMBL7433864 | 0.79 | TUBB4A (0.47) | ALDH1A1TDP1TUBB4ATUBBTUBA3C | |
| SCHEMBL2483754 | 0.77 | TSHR (0.52) | ALDH1A1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL397931 | 0.77 | TDP1 (0.66) | ALDH1A1TDP1TUBB4ATUBBTUBA3C | |
| SCHEMBL317536 | 0.77 | ALDH1A1 (0.66) | ALDH1A1TDP1TUBB4ATUBBTUBA3C | |
| SCHEMBL29650091 | 0.77 | ALDH1A1 (0.61) | ALDH1A1TDP1TUBB4ATUBBTUBA3C | |
| SCHEMBL5163347 | 0.77 | TSHR (0.56) | ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL29351649 | 0.77 | TDP1 (0.66) | ALDH1A1TDP1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753731-A | Preparation method of 3-amino-4-methoxybenzaniline | 嘉兴科隆化工有限公司 | 2016-07-13 | — | — | CN | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| CN-105753731-B | A kind of preparation method of the methoxybenzoyl aniline of 3 amino 4 | 嘉兴科隆化工有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-105753731-A | Preparation method of 3-amino-4-methoxybenzaniline | 嘉兴科隆化工有限公司 | 2016-07-13 | — | — | CN | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7160874-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6855706-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| EP-1233013-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-08-21 | — | — | EP | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-4500709-A | INTERMEDIATES IN THE PREPARATION OF CEPHALOSPORIN COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-02-19 | — | — | US | disclosed |
| US-4371531-A | OXIME-SUBSTITUTED ANTIBIOTICS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1983-02-01 | — | — | US | disclosed |
| US-4242510-A | Cephalosporin compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | ITGB4, ITGA4, ITGAL | ALDH1A1 912/4885TDP1 2797/4885TUBB4A 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.